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Bronchial hyperresponsiveness to 5-adenosine mono-phosphate (AMP) is a marker of airway
inflammation. Inhaled corticosteroids and antileukotrienes are used as anti-inflammatory
drugs for the treatment of asthma. To find out if these two drugs exert their protection in
an additive fashion, we compared the effects of acute treatment with inhaled beclomethasone
(BDP) and montelukast (ML), alone or in combination, on methacholine and AMP induced
bronchoconstriction.
15 asthmatic patients undertook methacholine and AMP challenges at baseline and after
receiving ML or BDP, alone or in combination, in a randomized, double-blind, double-dummy
placebo-controlled, crossover design.
BDP pretreatment significantly increased the AMP PC20 value (68.34  15.9 mg/mL) as
compared to placebo (22.87  5.7 mg/mL). Combined treatment, BDP plus ML, afforded
a further significant increase of AMP PC20 (154.57 55.0 mg/mL) as compared to each single
treatment. The significant protection exerted by combined treatment as compared to each
single active treatment was also demonstrated by the change of AMP PC20 doubling dose as
compared to placebo and each single active treatment.
Our findings suggest that these two agents exert their acute additive protection against AMP
induced bronchoconstriction acting on distinct inflammatory pathways and their combined use
might provide greater protection against inflammatory response elicited by AMP than either
drug alone.
ª 2010 Elsevier Ltd. All rights reserved.5 7593535; fax: þ39 095 330707.
yahoo.it (C. Mastruzzo).
0 Elsevier Ltd. All rights reserved.
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Bronchial hyperresponsiveness (BHR) and chronic airway
inflammation are key features of asthma. Inhaled cortico-
steroids (ICS), as effective anti-inflammatory drugs, are
widely used for the treatment of asthma and have shown to
be able to reduce airway inflammation, asthma symptoms
and improve lung function.1 Corticosteroids affect many
aspects of the inflammatory process increasing the tran-
scription of genes encoding anti-inflammatory mediators
and inhibiting the synthesis and release of proinflammatory
mediators, particularly cytokines. More recently, ICS have
also demonstrated to possess acute nongenomic anti-
inflammatory effects that might have potentially
beneficial effects in asthma.2 However, despite their
complex anti-inflammatory activity, ICS do not completely
abolish airway inflammation, thus suggesting that
other inflammatory mechanisms insensitive to the anti-
inflammatory effects of this class of drugs are also present
in bronchial asthma.
Among the inflammatory mediators involved in the
onset and maintenance of chronic airway inflammation,
cys-leukotrienes (cysLTs) are important candidate for
contributing to airways dysfunction in asthma.3 Cys-LTs,
through interaction with specific cysteinyl leukotriene -1
receptor (cys-LTR1), exert many biological effects that are
relevant to the pathophysiology of this disease, including
bronchoconstriction and chemoattraction for inflammatory
cells, especially eosinophils.4,5 Furthermore, there is
evidence that leukotriene synthesis and action are
relatively resistant to the anti-inflammatory activity played
by glucocorticoids,6,7 suggesting this, that the contempo-
raneous use of steroids and specific cys-LTR1 receptor-
antagonist, such as montelukast, may produce multiple
beneficial effects acting on different steps of the
inflammatory cascade.
Bronchial responsiveness to 50-adenosine mono-phos-
phate (AMP) is closely related to airway inflammation and
BHR to AMP has been proposed as a highly specific marker of
airway inflammation in asthma.8 Airway responsiveness to
AMP has been demonstrated to be correlated with airway
eosinophils,9 blood eosinophils and serum eosinophil
cationic protein levels 10 and modification in AMP respon-
siveness is related to inflammatory changes in airways.11,12
On the other hand, response to methacholine, a direct
stimulus widely used in clinical practice, reflects mainly
airway smooth muscle function, being only moderately
correlated with airway inflammation.13
Anti-inflammatory therapy, such as ICS, is able to reduce
BHR to AMP when used either as regular treatment14,15 or
acutely.16e18 Of note, the long-term therapy with anti-LTs
has also been demonstrated to protect against AMP induced
bronchoconstriction,19,20 although the ability of these drugs
to affect AMP response after acute treatment is not well
established.21,22
Aim of this study was to compare the effects of an acute
treatment with an ICS, beclomethasone diproprionate, and
an anti-cysLTs, montelukast, alone or in combination, on
the bronchoconstriction induced by AMP and methacholine.
Considering that beclomethasone diproprionate (BDP)
andmontelukast (ML) act on distinct inflammatory pathwayswehypothesized that the contemporaneous acute treatment
with these two drugs may provide an additive anti-
inflammatory effect with a greater protection against AMP
induced bronchoconstriction compared to the effect of
either drug alone.Methods
Subjects
Fifteen non-smoking subjects 18e34 yr of age (9 male, 6
female) (Table 1) took part in the study. Each had mild
persistent asthma, according to the GINA (Global Initiative
for Asthma) guidelines,1 with FEV1 80% of predicted. All
patients demonstrated a positive skin test in response to
common airborne allergens (dermatophagoides pter-
onissinus, dermatophagoides farinae, wall pellitory grass,
mixed grass pollens, cat fur), and a documented sensitivity
to methacholine and AMP during the previous 4 weeks. Each
subject had infrequent symptoms controlled with occa-
sional inhaled short acting inhaled b2-agonists alone and
each had not used ICS, oral corticosteroids, theophylline,
antihistamines, sodium cromoglycate, CysLTR1 receptor-
antagonist, inhaled long acting bronchodilatators within
the preceding 8 weeks. None had an exacerbation of
asthma or a respiratory tract infection during the preceding
8 weeks. Throughout the study, only short acting inhaled
beta2-adrenoreceptor agonists were allowed, but were
withheld for at least 8 h prior to each visit to the labora-
tory. All visits to the laboratory were carried out at the
same time of day, in order to avoid change in the response
due to diurnal variation, and outside the pollen season. The
study was approved by the local Ethic Committee and all
subjects gave their written informed consent.
Bronchial provocation test
Changes in airway calibre were measured indirectly using
FEV1 with a Turbin Spirometer (mkit, COSMED, Roma, Italy)
and the better of two consecutive measurements was used
for analysis. AHR was evaluated by means of methacholine
and AMP bronchial challenge performed according to rec-
ommended guidelines and as previously described.23e25 In
brief, methacholine (Sigma Chemical Co., St Louis, Missouri,
USA) and adenosine 50-monophosphate (Sigma) were made
up in phosphate-buffered saline (PBS) and 0.9% sodium
chloride to produce a range of increasing doubling concen-
trations of 0.03e16.00 mg/ml and 3.125e800 mg/ml,
respectively. The aqueous solutions were administered as
aerosols, generated from a starting volume of 3 ml, in
a disposable Inspiron Mininebulizer (C.R. Bard International,
Sunderland, UK) driven by compressed air at 8 l/min.
Patients inhaled increasing doubling concentrations of
agonist in five breaths from functional residual capacity to
total lung capacity through a mouthpiece, and FEV1 was
measured at 1 and 3 min after each administration. The
challenges were stoppedwhen a decrease of 20% in FEV1 had
been achieved or when the maximum concentration of
agonist had been inhaled. The bronchial responses to the
inhaled agonists were expressed as the provocative










1 M 21 95 14.19 0.15 Da
2 M 29 96 2.73 0.16 WeD
3 F 18 101 19.30 0.34 WeD
4 M 29 84 5.03 0.28 WeD
5 F 18 92 19.12 0.24 WeD
6 F 32 80 11.24 0.36 D
7 F 28 96 21.90 0.70 WeD
8 M 22 80 20.06 0.90 Wb
9 F 26 91 8.21 0.70 W
10 M 29 122 29.40 0.17 W
11 M 22 81 21.90 0.79 WeD
12 F 34 83 15.02 0.23 D
13 M 28 90 27.66 0.21 W
14 M 30 85 25.76 0.26 WeD
15 M 20 86 41.68 0.33 WeD
Mean SE 25.73  1.33 90.8 2.80 18.88 2.61 0.39 0.06
a Dermatophagoides.
b Wall pellitory grass.
Montelukast and ICS reduce AMP induced BHR 1419concentration causing a 20% decrease in FEV1 (PC20) value,
which was calculated by means of linear interpolation from
the concentrationeresponse curve constructed on a loga-
rithmic scale.
Study design
The study consisted of 5 visits to the clinic. On the
screening visit (visit 1) the following were assessed: eligi-
bility, demographic data, medical history, medications and
concentrationeresponse studies with inhaled methacholine
followed, 3 h apart, by an AMP challenge in the absence of
any drug treatment. On this occasion, as well as in the
other study days, the 3 h interval between the two chal-
lenges warranted a complete recovery of FEV1 to baseline
after the methacholine challenge.
Then, patients attended the laboratory on four separate
occasions, at least 7 days apart (visits 2e5) to undertake
concentrationeresponse studies with inhaled methacholine
and AMP after receiving BDP or ML, alone or in combination,
in a randomized, double-blind, double-dummy placebo-
controlled, crossover design. Patients were randomized
using an appropriate table of random numbers to receive all
possible combinations of drug administration (oral ML plus
inhaled BDP, oral ML plus inhaled placebo, oral placebo plus
inhaled BDP, oral placebo plus inhaled placebo). Mon-
telukast and its matched placebo were kindly supplied by
Merck Sharp & Dohme (Rome, West Point, PA, USA). BDP
and its matched placebo were kindly supplied by Chiesi
Farmaceutici (Parma, Italy). In order to ensure an adequate
drug activity, the timing of both drug administrations was
established according to previous observations.16,26e28
Particularly, it has been shown that ML achieves the plas-
matic peak approximately 3 h after administration27 while
a single dose of ICS was shown to protect against bronchial
provocation tests from 10 min after inhalation.26 Oral ML
(one tablets of 10 mg) or its matched placebo wasadministered 3 h prior to the challenge with methacholine.
Inhaled BDP (20 mg) or its matched placebo were adminis-
tered 30 min prior to the challenge with methacholine and
30 minutes prior to the challenge with AMP.
For those patients who did not demonstrate a 20%
decrease in FEV1 after inhalation of the last concentration
of either spasmogen solution, the log PC20 was taken as the
highest concentration (1600 mg/mL for methacholine,
800 mg/mL for AMP) and included in the analysis as
extrapolated data.
Data analyses
Results are expressed as mean SE unless otherwise spec-
ified and p< 0.05 was accepted as the minimum level of
statistical significance. Pre and post-treatment baseline
values of FEV1 prior to bronchial challenge were compared
between and within study days by two-way analysis of
variance (ANOVA). Values of methacholine and AMP PC20
following treatment with each combinations of drugs were
logarithmically transformed to normalize their distribution
and compared by one-way analysis of variance (ANOVA)
followed by NeumanneKeuls test, for specific means
comparisons, where appropriate.
The protective effect of each drug treatment on
responses to provocation of each challenge was also calcu-
lated by measuring the change in log PC20 from the baseline
after all active and placebo treatments in each subject and
expressed in terms of doubling doses using the formula:
ðlog10 PC20 active treatment log10 PC20 placeboÞOlog10 2
The lower is the value of the doubling dose the higher is
the bronchial responsiveness to each spasmogen. One-way
analysis of variance (ANOVA) followed by NeumanneKeuls
test was used to compare post-drug variations in BHR to
methacholine and AMP.
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There was no significant difference in baseline values of
FEV1 between any of the study days, and, in each study day,
between baseline FEV1 values before methacholine and
AMP challenges.
Administration of each drug (placebo, BDP or ML) did not
cause any significant change in FEV1 from baseline. Inhaled
methacholine and AMP in the absence of any drug treat-
ment produced a concentration-related bronchospasm with
a geometric mean (M) PC20 values of 0.39 0.06 mg/mL and
18.88 2.61 mg/mL, respectively.
Changes of methacholine responsiveness after drug
treatment
Placebo administration did not produce any significant
change in methacholine responsiveness in comparison to
baseline value. BDP or ML alone did not have a significant
protective effect against methacholine challenge;
pretreatment with BDP plus ML significantly increased
methacholine PC20 value to 0.93 0.40 mg/mL comparing
to baseline and placebo (p< 0.01 and p< 0.05 respectively)
(Fig. 1).
Then, we expressed the protective effect of each
treatment on methacholine-induced bronchoconstriction as
doubling dose. A mean protection of 1.11 0.21,
0.28 0.17 and 1.70 0.34 doubling doses for BDP, ML and
combined BDP plus ML were reported, respectively. Only
the protective effect of combined treatment (BDPþML) as
compared to placebo achieved significance (p< 0.001).
Changes of AMP responsiveness after drug
treatment
BDP pretreatment significantly (p< 0.01) increased the
AMP PC20 value (58.34 15.90 mg/mL) as compared to
placebo (PC20 value 22.87 5.70). ML also produced an
increase in the AMP PC20, but it did not reach a statisticalFigure 1 Effect of placebo (P), beclomethasone (BDP) and
montelukast (ML), alone and associated, on methacholine-
induced bronchoconstriction in asthmatic subjects. The PC20
values, after a logarithmic conversion, are expressed as
a geometric mean SE.significance. Combined treatment, BDP plus ML, afforded
a significant increase of AMP PC20 (PC20 value
154.57 55.0 mg/mL) as compared to baseline and each
single treatment (Figs. 2 and 3).
Then, changes in the protective effect of each drug
treatment on AMP induced bronchoconstriction were
expressed as doubling dose. BDP significantly reduced BHR
to AMP by 1.75 0.22 doubling doses as compared to
placebo. Combined treatment with BDP plus ML signifi-
cantly reduced airway responsiveness to AMP as compared
to the placebo and each single active treatment (Fig. 4).
Discussion
Bronchial hyperresponsiveness measured by bronchial
challenge with direct and indirect agonists is a character-
istic feature of bronchial asthma. The direct bronchocon-
strictors act on airway smooth muscle receptors (e.g.,
acetylcholine and muscarinic analogues on muscarinic
receptors, histamine on H1 receptors) to induce broncho-
constriction. On the other hand, indirect stimuli such as
AMP and mannitol are intrinsically dependent on primary
airway inflammation to mediate their downstream
constrictor effects and are thought to represent a more
physiological model of asthmatic airway narrowing than
their directly irritant counterparts of methacholine and
histamine challenge.13
The present study demonstrates that, in asthmatic
patients, acute combined treatment with ICS and anti-
leukotrienes provides greater protection against induced
bronchoconstriction compared to the effect of either drug
alone. The protection afforded by combined treatment was
greater against bronchoconstriction induced by AMP than
methacholine. Because AMP produces bronchoconstriction
through the release of inflammatory mediators from mast
cells, this suggests that acute combined treatment, actingFigure 2 Effect of placebo (P), beclomethasone (BDP) and
montelukast (ML), alone and associated, on 50-AMP-induced
bronchoconstriction in asthmatic subjects. The PC20 values,
after a logarithmic conversion, are expressed as a geometric
mean SE.
Figure 3 Effect of placebo (A), BDP (-), ML (:) and BDP plus ML (C) on the concentrationeresponse curves to inhaled 5-AMP
in 15 subjects with asthma.
Montelukast and ICS reduce AMP induced BHR 1421in an independent fashion, confers additive anti-inflam-
matory benefits as compared to the single drug treatment.
Several lines of evidence suggest that endogenous
adenosine contributes to the pathophysiology of asthma,8
primarily through the stimulation of adenosine A2B recep-
tors on “primed” mast cells29 so inducing the generationFigure 4 Doubling dose difference from baseline values for
each treatment: placebo (P), beclomethasone (BDP) and
montelukast (ML), alone and associated. Combined treatment
caused a significant double dose difference as compared to
each single active treatment. Results are expressed as
mean SE.and the release of inflammatory mediators such as hista-
mine, lypoxygenase products, tryptase, interleukins and
other cytokines. Inhalation of exogenous AMP is able to
induce a rapid inflammatory response with increase of
eosinophils and cys-LTs in the airway of asthmatic
subjects.30,31 AMP induced bronchoconstrictive effects are
proportional to the degree of inflammatory cell airway
infiltration, and AMP challenge, better than other stimuli
such as methacholine, has been suggested as a highly
sensitive marker of disease activity for monitoring asthma
control and to identify success of treatment.11,12
ICS and antileukotrienes are used as maintenance
therapy in persistent bronchial asthma,1 and it has been
suggested that these drugs may act on the different steps of
the inflammatory cascade. It has also been observed that
the addition of antileukotrienes to inhaled corticosteroids
is able to induce a reduction of surrogate airway inflam-
matory markers,32 including exhaled nitric oxide and blood
eosinophils, and better asthma control.33
A number of studies have demonstrated that long-term
therapy with ICS and antileukotrienes either alone or in
combination protects against AMP induced bronchocon-
striction, mainly reducing airway inflammatory cells,
including mast cells and eosinophils.14,15,19,20,34,35
However, the effect of acute treatment of both drugs on
AMP induced bronchoconstriction has not been fully inves-
tigated. In a limited number of previous studies, ICS acute
treatment demonstrated a short-term protective effect
against AMP bronchial hyperresponsiveness.16e18 The
protective capacity of a single dose of inhaled corticoste-
roid against AMP induced bronchoconstriction was also
1422 C. Mastruzzo et al.observed in our asthmatic patients. Of interest, in our study
the acute protective effect of a single glucocorticoid
inhalation was obtained by using a lower dose of ICS as
compared to those used in most of previous studies. These
findings underline the high sensitivity to the effect of ICS of
the airway response to inhaled AMP that has been recently
pointed out.11
As regards to the protective efficacy of acute treatment
with antileukotrienes against AMP induced bronchocos-
triction in asthmatic patients, previous reports suggested
that montelukast possesses a protective effect.21,22 In
a recent study, a two-day course of therapy with oral
montelukast produced a small but significant protection
against AMP induced bronchoconstriction,21 whereas in
another study the administration of a single dose of oral
montelukast, although it did not produce significant
improvement in airway sensitivity to AMP, induced a signif-
icantly more rapid recovery of FEV1 after the AMP chal-
lenge.22 In the present study, a single dose of montelukast
exerts a small protective effect against AMP induced
bronchoconstriction, but it did not reach statistic signifi-
cance. However, interestingly, the addition of montelukast
to a single dose of inhaled BDP produced a protective effect
on AMP induced bronchoconstriction significantly higher as
compared to single treatment with BDP. Thus, our results
support the hypothesis that contemporaneous administra-
tion of ICS and antileukotrienes act acutely on different
inflammatory pathways within the inflammatory cascade
that is activated during AMP induced bronchospasm.
In our study, acute combined treatment also provides
protection against bronchoconstriction induced by meth-
acholine, while each single active treatment (BDP or mon-
telukast) did not. However, the protection afforded by
combined treatment (BDP plus montelukast) against meth-
acholine was less relevant than that observed against AMP.
Thismight be strictly correlated to the differentmechanisms
of bronchoconstrictionelicitedbymethacholine in respect of
those by AMP. Methacholine acts directly on acetylcholine
receptors on smooth muscle causing contraction and airway
narrowing. As a consequence, BHR to methacholine in asth-
matic patients correlates mainly to structural changes
following airway remodelling due to increased airway
smooth muscle contractile properties, sub-epithelial retic-
ular basement thickness and, only moderately, with airway
inflammation.13 Following this, in asthmatic patients
hyperresponsiveness to methacholine has been found to be
mainly related to FEV1, while the level of AMP PC20 was
predominantly predicted by the percentage of sputum
eosinophils.9 In the present study, we demonstrated that the
combined anti-inflammatory protection afforded by
contemporaneous acute treatment with BDP and ML had
a greater effect on responsiveness to AMP than methacho-
line. Our findings well correspond to previous studies
demonstrating that indirect airway responsiveness to AMP is
more closely linked with airway inflammation than does
direct airway methacholine responsiveness.9
Acute anti-inflammatory effects of ICS have been
reported in previous studies.16e18,36e38 A single dose of ICS
showed to protect against bronchoconstriction induced by
indirect stimuli such as AMP,16e18 hypertonic solution36 and
exercise38 and inhibited nasal output of IL-5 and GM-CSF
following nasal allergen challenge.37 This rapid onset of theaction of ICS is thought to be mainly related to different
mechanisms than the conventional activation of nuclear
glucocorticoid receptors. These nongenomic effects
occurring acutely (within minutes) may include airway
vascular smooth muscle contraction, modulation of secre-
tory response of airway epithelium, and inhibition of mast
cell activation. Previous studies demonstrated that ICS
produce a transient decrease of airway blood flow and that
ICS induced acute vasoconstriction might have potentially
beneficial effects in asthma and could be considered as an
anti-inflammatory effect of ICS.2,39 Another possibility is
that ICS may acutely modulate the fluid balance in the
airway wall acting on the secretory response of the airway
epithelium.40 Finally, a recent study26 demonstrated that
a single dose of BDP had a rapid effect on reducing the
airway reactivity to hyperpnea and the urinary excretion of
LTE4 and the bronchoconstrictive mediators 9a, 11b-PGF
(considered a sensitive marker of mast cell activation).
These findings suggest that ICS may acutely regulate mast
cell release of mediators, probably through a reduction in
intracellular calcium.41
According to this data, it is conceivable that the acute
ICS protective effect on induced bronchoconstriction which
we observed in our patients 30 min after BDP inhalation was
mainly related to the nongenomic anti-inflammatory
effects of BDP. As regards to the protective effect observed
on AMP BHR, it cannot be excluded that the administration
of BDP before methacholine challenge could have produced
a genomic anti-inflammatory effect contributing to the
protective effect observed at the time of AMP challenge,
3 h later. However, considering the low dose of inhaled
steroid used, it can be surmised that the observed protec-
tive effect on AMP challenge is mainly related to the acute
nongenomic anti-inflammatory effects of BDP inhaled
30 min prior to the AMP challenge.
In patients with asthma the CysLTs are known to be
either potent inducers of bronchoconstriction and media-
tors of airway inflammation.4,5 Leukotriene receptor-
antagonists attenuate the proinflammatory effects of
leukotrienes, such as increased microvascular permeability,
eosinophil chemotaxis, mucus secretion, as well as blocking
leukotriene-induced smooth muscle constriction and
proliferation.42 It is also well recognized that leukotriene
synthesis and action is relatively resistant to the glucocor-
ticoid activity.6,7,43 Mechanisms by which antileukotriene
adding exerts an acute additional protective effect on AMP
induced bronchoconstriction as compared to BDP treatment
may be mainly related to the lack of effectiveness of
corticosteroid on leukotrienes pathway. The early genera-
tion and the release of lypoxygenase inflammatory products
occurring soon after AMP challenge,31 and the following
bronchoconstrictor response could be poorly controlled by
corticosteroid treatment while it is effectively counter-
acted by previous administration of a specific CysLTR1
receptor-antagonist, such as montelukast which rapidly
attenuates the proinflammatory effects of leukotreines, as
well as blocks leukotriene-induced smooth cell muscle
constriction. These findings are consistent with previous
clinical studies where acute or regular treatment with
montelukast conferred additive beneficial effects on AMP
BHR in patients who were suboptimally controlled with ICS
monotherapy.34,44
Montelukast and ICS reduce AMP induced BHR 1423Of interest, results from this study support previous
clinical reports showing that adding montelukast to steroids
in acute treatment of asthma exacerbation produces
additive clinical benefits and improvement in lung
function.45e47
In conclusion, although it is not possible to provide
a conclusive explanation for the mechanism by which ICS
and antileukotrienes exert an additional protective effect
on AMP induced bronchoconstriction, a selective and
complementary therapeutic activity of these two kinds of
drugs occurs. Considering the importance of AMP as a local
mediator involved in airway pathophysiology of bronchial
asthma, we believe that these findings may have clinical
relevance, suggesting that ICS and antileukotrienes exert
their activities in airways acting on distinct inflammatory
pathways and their acute combined use might provide
greater protection against inflammatory responses and
additional asthma control than either drug alone.
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